Cytokinetics Company Profile (NASDAQ:CYTK)

About Cytokinetics

Cytokinetics logoCytokinetics, Incorporated is a biopharmaceutical company. The Company is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates include tirasemtiv, CK-2127107 and omecamtiv mecarbil. Its lead drug candidate from its skeletal muscle contractility program, tirasemtiv, is a skeletal muscle troponin activator. The Company is developing CK-2127107, a skeletal muscle troponin activator. The Company has conducted approximately five Phase I clinical trials of CK-2127107. Its lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is a cardiac muscle myosin activator. COSMIC-HF is a Phase II, double-blind, randomized, placebo-controlled, multicenter, clinical trial designed to assess the pharmacokinetics and tolerability of omecamtiv mecarbil dosed orally in patients with heart failure and left ventricular systolic dysfunction.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CYTK
  • CUSIP:
Key Metrics:
  • Previous Close: $9.18
  • 50 Day Moving Average: $10.39
  • 200 Day Moving Average: $9.06
  • 52-Week Range: $6.00 - $13.18
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.85
  • P/E Growth: -0.45
  • Market Cap: $364.47M
  • Outstanding Shares: 39,703,000
  • Beta: 1.29
Profitability:
  • Net Margins: -132.01%
  • Return on Equity: -69.51%
  • Return on Assets: -38.59%
Debt:
  • Debt-to-Equity Ratio: 0.61%
  • Current Ratio: 3.68%
  • Quick Ratio: 3.68%
Additional Links:
Companies Related to Cytokinetics:

Analyst Ratings

Consensus Ratings for Cytokinetics (NASDAQ:CYTK) (?)
Ratings Breakdown: 7 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $19.14 (108.53% upside)

Analysts' Ratings History for Cytokinetics (NASDAQ:CYTK)
Show:
DateFirmActionRatingPrice TargetDetails
9/9/2016FBR & CoReiterated RatingBuyView Rating Details
9/1/2016Needham & Company LLCReiterated RatingBuy$17.00View Rating Details
8/18/2016Roth CapitalReiterated RatingBuy$22.00View Rating Details
8/2/2016JMP SecuritiesReiterated RatingBuy$17.00View Rating Details
7/12/2016Piper Jaffray Cos.Reiterated RatingOverweight$24.00View Rating Details
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$16.00 -> $14.00View Rating Details
2/17/2016Cowen and CompanyReiterated RatingBuy$16.00View Rating Details
7/24/2015MLV & Co.Reiterated RatingBuy$9.00 -> $14.00View Rating Details
(Data available from 10/1/2014 forward)

Earnings

Earnings History for Cytokinetics (NASDAQ:CYTK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/27/2016        
7/28/2016Q2($0.28)($0.29)ViewListenView Earnings Details
4/28/2016Q1($0.37)($0.31)ViewListenView Earnings Details
2/16/2016Q415($0.32)($0.24)$10.49 million$9.80 millionViewListenView Earnings Details
10/29/2015Q315($0.30)($0.23)$11.24 million$7.90 millionViewListenView Earnings Details
4/30/2015Q1($0.12)($0.23)$10.10 million$4.40 millionViewListenView Earnings Details
2/12/2015Q4($0.17)$0.23$10.80 million$21.80 millionViewListenView Earnings Details
10/30/2014Q3($0.27)($0.16)ViewListenView Earnings Details
7/30/2014Q2($0.32)($0.23)$7.01 million$7.80 millionViewListenView Earnings Details
5/6/2014Q1($0.34)($0.27)$7.69 million$8.00 millionViewListenView Earnings Details
2/6/2014Q4($0.08)$0.21$19.14 million$24.30 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cytokinetics (NASDAQ:CYTK)
Current Year EPS Consensus Estimate: $-1.2 EPS
Next Year EPS Consensus Estimate: $-1.57 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.33)($0.33)($0.33)
Q2 20161($0.39)($0.39)($0.39)
Q3 20161($0.42)($0.42)($0.42)
Q4 20161($0.44)($0.44)($0.44)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Cytokinetics (NASDAQ:CYTK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Cytokinetics (NASDAQ:CYTK)
Insider Ownership Percentage: 5.10%
Institutional Ownership Percentage: 67.32%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/31/2015L Patrick GageDirectorBuy1,000$6.95$6,950.00View SEC Filing  
8/20/2015L Patrick GageDirectorBuy10,000$6.55$65,500.00View SEC Filing  
5/6/2015L Patrick GageDirectorBuy10,000$5.71$57,100.00View SEC Filing  
3/11/2015Andrew A WolffCMOSell21,875$7.80$170,625.00View SEC Filing  
12/30/2014Fady Ibraham MalikSVPSell21,630$6.73$145,569.90View SEC Filing  
5/9/2014L Patrick GageDirectorBuy10,850$4.09$44,376.50View SEC Filing  
2/25/2014Eastern Capital Ltdmajor shareholderBuy500,000$8.00$4,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Cytokinetics (NASDAQ:CYTK)
DateHeadline
streetinsider.com logoCytokinetics (CYTK) Announces Early HSR Act Termination in ... - StreetInsider.com (NASDAQ:CYTK)
www.streetinsider.com - September 29 at 9:32 AM
publicnow.com logoCytokinetics Announces Early Termination of Hart-Scott-Rodino Waiting Period for Expanded Collaboration With Astellas (NASDAQ:CYTK)
www.publicnow.com - September 29 at 9:32 AM
nasdaq.com logoNoteworthy Friday Option Activity: CNP, CAT, CYTK - Nasdaq (NASDAQ:CYTK)
www.nasdaq.com - September 24 at 9:13 AM
News IconNoteworthy Friday Option Activity: CNP, CAT, CYTK (NASDAQ:CYTK)
www.stockoptionschannel.com - September 23 at 4:20 PM
News IconCytokinetics Inc. (CYTK) Stock Price Up 3.3% - NewsDen (NASDAQ:CYTK)
newsden.net - September 22 at 4:40 PM
streetinsider.com logoCytokinetics (CYTK) Presents Additional COSMIC-HF Data; Possible Improvement in Symptoms Noted - StreetInsider.com (NASDAQ:CYTK)
www.streetinsider.com - September 19 at 3:25 PM
4-traders.com logoCytokinetics Announces Presentation of Additional Results From COSMIC-HF at the HFSA Annual Scientific Meeting (NASDAQ:CYTK)
www.4-traders.com - September 19 at 9:12 AM
biz.yahoo.com logoCYTOKINETICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:CYTK)
biz.yahoo.com - September 19 at 9:12 AM
News IconCytokinetics (NASDAQ:CYTK) Sellers Covered 0.13% of Their Shorts - Post News (NASDAQ:CYTK)
www.kentuckypostnews.com - September 17 at 4:26 PM
streetinsider.com logoCytokinetics (CYTK) Says Additional Results From COSMIC-HF to Be Presented at HFSA - StreetInsider.com (NASDAQ:CYTK)
www.streetinsider.com - September 10 at 9:08 AM
finance.yahoo.com logoCytokinetics Announces Additional Results From COSMIC-HF to Be Presented at the HFSA Annual Scientific Meeting (NASDAQ:CYTK)
finance.yahoo.com - September 9 at 4:24 PM
streetinsider.com logoForm 8-K CYTOKINETICS INC For: Sep 08 - StreetInsider.com (NASDAQ:CYTK)
www.streetinsider.com - September 8 at 8:20 AM
publicnow.com logoCytokinetics Announces Next-Generation Fast Skeletal Muscle Activator Entering IND-Enabling Studies (NASDAQ:CYTK)
www.publicnow.com - September 8 at 8:20 AM
capitalcube.com logoETF’s with exposure to Cytokinetics, Inc. : September 6, 2016 (NASDAQ:CYTK)
www.capitalcube.com - September 6 at 4:26 PM
News IconExpert Analysts Sentiments for: Cytokinetics, Incorporated (NASDAQ:CYTK) , Methode Electronics, Inc. (NYSE:MEI) - Wall Street Times (press release) (NASDAQ:CYTK)
www.wallstreetnews24.com - September 3 at 4:15 PM
News IconMost Volatile Biotech Stocks- Array BioPharma (NASDAQ:ARRY), Cytokinetics (NASDAQ:CYTK) - Seneca Globe (NASDAQ:CYTK)
www.senecaglobe.com - September 3 at 4:15 PM
thecountrycaller.com logoHere's Why You Should Buy Cytokinetics, Inc. (CYTK) As Amgen, Inc. (AMGN) Enters Phase 3 Study - TCC (NASDAQ:CYTK)
www.thecountrycaller.com - September 3 at 4:15 PM
News IconAmgen to Advance Omecamtiv Mecarbil to Phase 3 Clinical Development (NASDAQ:CYTK)
www.biomedreports.com - September 2 at 4:21 PM
capitalcube.com logoCytokinetics, Inc. breached its 50 day moving average in a Bearish Manner : CYTK-US : September 2, 2016 (NASDAQ:CYTK)
www.capitalcube.com - September 2 at 9:23 AM
nasdaq.com logoNoteworthy Thursday Option Activity: SGMS, CYTK, GCO (NASDAQ:CYTK)
www.nasdaq.com - September 1 at 4:27 PM
News IconCytokinetics Heart Drug Moves to Late-Stage Development (NASDAQ:CYTK)
ih.advfn.com - September 1 at 4:27 PM
thestreet.com logoWill Cytokinetics (CYTK) Stock Be Helped by Cardiovascular Drug Advancement? (NASDAQ:CYTK)
www.thestreet.com - September 1 at 4:27 PM
biz.yahoo.com logoCYTOKINETICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements a (NASDAQ:CYTK)
biz.yahoo.com - September 1 at 4:27 PM
finance.yahoo.com logo8:33 am Cytokinetics to advance omecamtiv mecarbil to Phase 3 clinical trial; Amgen (AMGN (NASDAQ:CYTK)
finance.yahoo.com - September 1 at 9:44 AM
publicnow.com logoCytokinetics and Amgen to Advance Omecamtiv Mecarbil to Phase 3 Clinical Development (NASDAQ:CYTK)
www.publicnow.com - September 1 at 9:44 AM
finance.yahoo.com logoWhy You Shouldn't Bet Against Cytokinetics (CYTK) Stock (NASDAQ:CYTK)
finance.yahoo.com - August 30 at 4:33 PM
rttnews.com logoJNP Will Bleed On Failed Trial, CERU Crashes, CYTK Progresses With VITALITY (NASDAQ:CYTK)
www.rttnews.com - August 18 at 4:35 PM
streetinsider.com logoCytokinetics (CYTK) Announces Completion of VITALITY-ALS Patient Enrollment (NASDAQ:CYTK)
www.streetinsider.com - August 18 at 4:35 PM
streetinsider.com logoCytokinetics (CYTK) Announces Completion of VITALITY-ALS Patient Enrollment - StreetInsider.com (NASDAQ:CYTK)
www.streetinsider.com - August 18 at 9:13 AM
biz.yahoo.com logoCYTOKINETICS INC Files SEC form 8-K, Other Events (NASDAQ:CYTK)
biz.yahoo.com - August 17 at 8:50 AM
publicnow.com logoCytokinetics Completes Enrollment in VITALITY-ALS, Phase 3 Clinical Trial of Tirasemtiv in Patients With ALS (NASDAQ:CYTK)
www.publicnow.com - August 17 at 8:50 AM
finance.yahoo.com logoCYTOKINETICS INC Financials (NASDAQ:CYTK)
finance.yahoo.com - August 12 at 4:34 PM
capitalcube.com logoETF’s with exposure to Cytokinetics, Inc. : August 11, 2016 (NASDAQ:CYTK)
www.capitalcube.com - August 11 at 4:39 PM
capitalcube.com logoCytokinetics, Inc. :CYTK-US: Earnings Analysis: Q2, 2016 By the Numbers : August 10, 2016 (NASDAQ:CYTK)
www.capitalcube.com - August 10 at 4:39 PM
biz.yahoo.com logoCYTOKINETICS INC Files SEC form 10-Q, Quarterly Report (NASDAQ:CYTK)
biz.yahoo.com - August 4 at 10:16 PM
News IconThese Biotech’s are Due for a Run (NASDAQ:CYTK)
www.ssuchronicle.com - August 4 at 4:47 PM
finance.yahoo.com logoCytokinetics (CYTK) Shares March Higher, Can It Continue? (NASDAQ:CYTK)
finance.yahoo.com - August 4 at 4:47 PM
smarteranalyst.com logoJMP Securities Bullish on Cytokinetics, Inc. (CYTK) Following 2Q Update; Sees Key Catalysts on Track - Smarter Analyst (NASDAQ:CYTK)
www.smarteranalyst.com - August 2 at 9:20 AM
istreetwire.com logoStocks To Watch: Intrexon Corporation (XON), Cytokinetics, Incorporated (CYTK), Alder Biopharmaceuticals Inc. (ALDR) - iStreetWire (NASDAQ:CYTK)
istreetwire.com - August 1 at 4:29 PM
4-traders.com logoCytokinetics : reports 2Q loss (NASDAQ:CYTK)
www.4-traders.com - July 29 at 9:54 PM
streetinsider.com logoCytokinetics (CYTK), Astellas Pharma Expand Colaboration into ALS (NASDAQ:CYTK)
www.streetinsider.com - July 29 at 9:54 PM
News IconBiotech Roundup: Gilead Slump, Celgene Goes Trump, Hemo Data & More - Xconomy (NASDAQ:CYTK)
www.xconomy.com - July 29 at 4:37 PM
ftsenews.co.uk logoNeedham reiterated Cytokinetics Inc (NASDAQ:CYTK) as 'Buy' With 17 PT - FTSE News (NASDAQ:CYTK)
www.ftsenews.co.uk - July 29 at 4:37 PM
seekingalpha.com logoCytokinetics's (CYTK) CEO Robert Blum on Q2 2016 Results - Earnings Call Transcript - Seeking Alpha (NASDAQ:CYTK)
seekingalpha.com - July 29 at 8:24 AM
globenewswire.com logoCytokinetics, Inc. Reports Second Quarter 2016 Financial Results ... - GlobeNewswire (press release) (NASDAQ:CYTK)
globenewswire.com - July 29 at 8:24 AM
streetinsider.com logoCytokineti cs(CYTK) Notches New Milestone with Expanded Astellas Partnership - Roth Capital (NASDAQ:CYTK)
www.streetinsider.com - July 28 at 5:36 PM
globenewswire.com logoCytokinetics, Inc. Reports Second Quarter 2016 Financial Results (NASDAQ:CYTK)
globenewswire.com - July 28 at 5:36 PM
sg.finance.yahoo.com logoCytokinetics reports 2Q loss (NASDAQ:CYTK)
sg.finance.yahoo.com - July 28 at 5:21 PM
biz.yahoo.com logoQ2 2016 Cytokinetics Inc Earnings Release - 4:00 pm ET (NASDAQ:CYTK)
biz.yahoo.com - July 28 at 7:07 AM
globenewswire.com logoCytokinetics and Astellas Announce Option Right for Tirasemtiv and Expansion of Global Collaboration for CK ... - GlobeNewswire (press release) (NASDAQ:CYTK)
globenewswire.com - July 27 at 4:40 PM

Social

Cytokinetics (NASDAQ:CYTK) Chart for Saturday, October, 1, 2016


Last Updated on 10/1/2016 by MarketBeat.com Staff